Relative benefits of different antihypertensive drugs in the prevention of vascular complications

G. H. Rutan, William Cushman

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Large-scale clinical trials of antihypertensive drugs that have shown a reduction in morbidity and mortality used the classic step-care treatment design, initiating treatment with a diuretic. Long-term morbidity and mortality reponse comparing the newer classes of agents with the traditional antihypertensive agents have not been completed. A recent meta-analysis of 13 randomized, controlled clinical trials of hypertension showed that 18 elderly people, but two to four times as many younger peeple, needed to be treated for 5 years to prevent one cerebrovascular or cardiac event. Any head-to-head comparisons of one class of antihypertensive agent with another in the prevention of vascular complications will require very large cohorts, even of elderly people, to show a difference. Such trials are ongoing or being planned, but their results will not be available before the next century.

Original languageEnglish (US)
Pages (from-to)240-244
Number of pages5
JournalCurrent Opinion in Nephrology and Hypertension
Volume4
Issue number3
DOIs
StatePublished - Jun 22 1995
Externally publishedYes

Fingerprint

Antihypertensive Agents
Blood Vessels
Morbidity
Mortality
Diuretics
Meta-Analysis
Randomized Controlled Trials
Clinical Trials
Hypertension
Therapeutics

All Science Journal Classification (ASJC) codes

  • Internal Medicine
  • Nephrology

Cite this

Relative benefits of different antihypertensive drugs in the prevention of vascular complications. / Rutan, G. H.; Cushman, William.

In: Current Opinion in Nephrology and Hypertension, Vol. 4, No. 3, 22.06.1995, p. 240-244.

Research output: Contribution to journalReview article

@article{40099fc4699041db91f68521b8607a40,
title = "Relative benefits of different antihypertensive drugs in the prevention of vascular complications",
abstract = "Large-scale clinical trials of antihypertensive drugs that have shown a reduction in morbidity and mortality used the classic step-care treatment design, initiating treatment with a diuretic. Long-term morbidity and mortality reponse comparing the newer classes of agents with the traditional antihypertensive agents have not been completed. A recent meta-analysis of 13 randomized, controlled clinical trials of hypertension showed that 18 elderly people, but two to four times as many younger peeple, needed to be treated for 5 years to prevent one cerebrovascular or cardiac event. Any head-to-head comparisons of one class of antihypertensive agent with another in the prevention of vascular complications will require very large cohorts, even of elderly people, to show a difference. Such trials are ongoing or being planned, but their results will not be available before the next century.",
author = "Rutan, {G. H.} and William Cushman",
year = "1995",
month = "6",
day = "22",
doi = "10.1097/00041552-199505000-00007",
language = "English (US)",
volume = "4",
pages = "240--244",
journal = "Current Opinion in Nephrology and Hypertension",
issn = "1062-4821",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Relative benefits of different antihypertensive drugs in the prevention of vascular complications

AU - Rutan, G. H.

AU - Cushman, William

PY - 1995/6/22

Y1 - 1995/6/22

N2 - Large-scale clinical trials of antihypertensive drugs that have shown a reduction in morbidity and mortality used the classic step-care treatment design, initiating treatment with a diuretic. Long-term morbidity and mortality reponse comparing the newer classes of agents with the traditional antihypertensive agents have not been completed. A recent meta-analysis of 13 randomized, controlled clinical trials of hypertension showed that 18 elderly people, but two to four times as many younger peeple, needed to be treated for 5 years to prevent one cerebrovascular or cardiac event. Any head-to-head comparisons of one class of antihypertensive agent with another in the prevention of vascular complications will require very large cohorts, even of elderly people, to show a difference. Such trials are ongoing or being planned, but their results will not be available before the next century.

AB - Large-scale clinical trials of antihypertensive drugs that have shown a reduction in morbidity and mortality used the classic step-care treatment design, initiating treatment with a diuretic. Long-term morbidity and mortality reponse comparing the newer classes of agents with the traditional antihypertensive agents have not been completed. A recent meta-analysis of 13 randomized, controlled clinical trials of hypertension showed that 18 elderly people, but two to four times as many younger peeple, needed to be treated for 5 years to prevent one cerebrovascular or cardiac event. Any head-to-head comparisons of one class of antihypertensive agent with another in the prevention of vascular complications will require very large cohorts, even of elderly people, to show a difference. Such trials are ongoing or being planned, but their results will not be available before the next century.

UR - http://www.scopus.com/inward/record.url?scp=0029040458&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029040458&partnerID=8YFLogxK

U2 - 10.1097/00041552-199505000-00007

DO - 10.1097/00041552-199505000-00007

M3 - Review article

VL - 4

SP - 240

EP - 244

JO - Current Opinion in Nephrology and Hypertension

JF - Current Opinion in Nephrology and Hypertension

SN - 1062-4821

IS - 3

ER -